CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.25
+0.03 (+2.46%)
As of 3:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.22
Open1.21
Bid1.23 x 1100
Ask1.26 x 1000
Day's Range1.21 - 1.27
52 Week Range1.06 - 6.00
Volume83,173
Avg. Volume279,569
Market Cap42.047M
Beta1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference

    LOS ANGELES, July 16, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, CytRx's President and Chief Operating Officer, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19 at 12:00 noon Eastern Daylight Time at Convene-Midtown West in New York, NY. Conference attendees consist of portfolio managers, hedge fund managers, family offices, and leading banking, trading and brokerage firms. CytRx Corporation (CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with cancer. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.  CytRx's website is www.cytrx.com.

  • PR Newswire21 days ago

    CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

    LOS ANGELES, June 28, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with triple negative breast cancer (TNBC). This is the third trial conducted by NantCell which will investigate aldoxorubicin combined with immunotherapy or high-affinity natural killer (haNK) cell therapy in certain high unmet need cancer indications.

  • PR Newswire24 days ago

    CytRx Corporation Joins Russell Microcap® Index

    LOS ANGELES, June 25, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has been added to the Russell Microcap® Index, effective upon the market opening today, Monday, June 25, 2018. "We are honored to be added to the Russell Microcap® Index," said  Eric Curtis, CytRx's President and Chief Operating Officer. The Russell indexes are broadly referenced as benchmarks by active investment strategists and institutional investors for index funds.

  • PR Newswire28 days ago

    CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology

    LOS ANGELES, June 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted data on NantCell Inc's aldoxorubicin which was published in the peer-reviewed journal Future Oncology. The paper, published on June 5, 2018, is entitled "Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma" and can be accessed online here.

  • PR Newswirelast month

    CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting

    LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, in Chicago. The data clearly demonstrates the lack of cardiac toxicity associated with treatment with aldoxorubicin.

  • PR Newswirelast month

    CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

    LOS ANGELES, June 4, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned subsidiary that will focus on advancing the Company's proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates.  CytRx has transferred to Centurion BioPharma all of the assets, liabilities and personnel associated with its laboratory operations in Freiburg, Germany. Administrative Offices are located in Los Angeles, California.

  • PR Newswire2 months ago

    CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference

    LOS ANGELES, May 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. John Caloz, Chief Financial Officer, will present at the 8th Annual LD Micro Invitational Conference on Tuesday, June 5, 2018 at 1:30 P.M. Pacific Daylight Time at the Luxe Sunset Boulevard Hotel in Bel-Air. Mr. Caloz will discuss the LADR™ platform, its broad potential in treating various tumor types, its advantages over antibody drug conjugates and an example of a LADR™ surrogate product proof of concept (aldoxorubicin).  He will also address the goal of obtaining pharmaceutical partnerships to develop the LADR™ pipeline candidates that are eligible for Investigational New Drug (IND)-enabling studies. In excess of 1,000 people are expected to attend the Invitational, to hear presentations from more than 200 leading microcap companies.

  • PR Newswire2 months ago

    CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting

    LOS ANGELES, May 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldoxorubicin will be featured in a poster presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, taking place June 1-5, 2018 in Chicago. The data were obtained from two clinical trials of aldoxorubicin, a rationally-engineered cytotoxic which employs a linker bound to albumin to deliver doxorubicin directly into the tumor.

  • PR Newswire2 months ago

    CytRx Announces Closing of $7.0 Million Registered Direct Offering

    After deducting the placement agent's fees and estimated offering expenses, the net proceeds to CytRx were approximately $6.5 million. CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers. The shares of common stock were sold pursuant to a "shelf" registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on April 21, 2017.

  • PR Newswire2 months ago

    CytRx Announces $7.0 Million Registered Direct Offering

    LOS ANGELES, May 11, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 5,600,000 shares of its common stock, at a purchase price of $1.25 per share, resulting in gross proceeds of $7.0 million. The offering is expected to close on or about May 15, 2018, subject to customary closing conditions. After deducting the placement agent's fees and estimated offering expenses, the net proceeds to CytRx are expected to be approximately $6.5 million. CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers.

  • Associated Press2 months ago

    CytRx: 1Q Earnings Snapshot

    On a per-share basis, the Los Angeles-based company said it had a loss of 15 cents. The company's shares closed at $1.89. A year ago, they were trading at $2.95. _____ This story was generated by Automated ...

  • PR Newswire2 months ago

    CytRx Reports First Quarter 2018 Financial Results

    LOS ANGELES , May 8, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ...

  • PR Newswire2 months ago

    CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018

    New President and Chief Operating Officer Mr. Eric Curtis will be Representing CytRx Corporation LOS ANGELES , May 7, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research ...

  • PR Newswire3 months ago

    CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer

    LOS ANGELES, May 3, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive management team, as President and Chief Operating Officer, effective today. Mr. Curtis brings 25 years of life science leadership experience to CytRx, with a proven track record in oncology and orphan diseases, including the development and commercialization of several approved and marketed cancer drugs such as Votrient®, Doxil®, Velcade®, Benlysta® and Tykerb®.  Most recently, he has provided strategic consultancy services to a variety of healthcare-focused companies, including CytRx.  Mr. Curtis' appointment strengthens the executive leadership team and adds significant development and operational expertise.

  • PR Newswire3 months ago

    CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting

    LOS ANGELES , April 30, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that an abstract submitted ...

  • PR Newswire3 months ago

    CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting

    LADR-7, LADR-8, LADR-9 and LADR-10 Demonstrate Robust Complete and Partial Responses and Long-Term Antitumor Activity in Melanoma, Lung, Breast, Ovarian, Head and Neck and Renal Cell Cancers Conference ...

  • PR Newswire3 months ago

    CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference

    Discussion Will Cover Developments with Big Pharma for Strategic Partnerships and Superiority of the LADR™ Platform Over Antibody-Drug Conjugates Conference Call and Webcast to be held on Wednesday, April ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMT

    Q4 2017 CytRx Corp Earnings Call

  • ACCESSWIRE4 months ago

    Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment

    Stock Monitor: CytRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Loxo Oncology, Inc. (NASDAQ: LOXO ). If you want ...

  • ACCESSWIRE4 months ago

    CytRx Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018 at 11:00 AM Eastern Time. ...

  • Associated Press4 months ago

    CytRx reports 4Q loss

    The Los Angeles-based company said it had a loss of 16 cents per share. The cancer drug developer posted revenue of $100,000 in the period. For the year, the company reported that its loss narrowed to ...

  • PR Newswire4 months ago

    CytRx Reports 2017 Financial Results

    Four New LADR™ Candidates with Breakthrough Potential Recently Selected for Advancement Into Investigational New Drug-Enabling Studies Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) ...

  • PR Newswire4 months ago

    CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference

    LOS ANGELES, March 16, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, Advisor to the Chairman and CEO, will present at the 28th Annual Oppenheimer Healthcare Conference on Wednesday, March 21, 2018 at 3:55 P.M. Eastern Daylight Time at the Westin New York Grand Central in New York, New York.

  • PR Newswire4 months ago

    CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials

    Supportive Data on All Candidates to be Highlighted in Poster Presentations at the Upcoming American Association for Cancer Research 2018 Annual Meeting Next Month LOS ANGELES , March 15, 2018 /PRNewswire/ ...

  • PR Newswire4 months ago

    CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018

    LOS ANGELES, March 12, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the full year ended December 31, 2017 on Monday, March 19, 2018. CytRx's executives Steven Kriegsman, Chairman and CEO, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the results. To access the conference call, dial 844-358-6753 (U.S. and Canada) or 216-562-0397 (international callers) and enter the conference ID number: 8178698.  A live and archived webcast will be available in the investor relations section of the company's website, www.cytrx.com.  A replay of the call and webcast will begin approximately two hours after the live call has ended.  To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 8178698.